NFA
IOVA icon

Nationwide Fund Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Nationwide Fund Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-29,827
Closed -$231K – 1017
2017
Q3 		$231K Sell
29,827
-109,459
-79% -$693K ﹤0.01% 2569
2017
Q2 		$1.02M Buy
139,286
+107,190
+334% +$681K ﹤0.01% 1766
2017
Q1 		$239K Sell
32,096
-2,373
-7% -$17.4K ﹤0.01% 2505
2016
Q4 		$240K Buy
34,469
+1,660
+5% +$11.4K ﹤0.01% 2521
2016
Q3 		$270K Buy
32,809
+2,702
+9% +$22.9K ﹤0.01% 2482
2016
Q2 		$244K Hold
30,107
– – ﹤0.01% 2513
2016
Q1 		$153K Hold
30,107
– – ﹤0.01% 2649
2015
Q4 		$232K Buy
30,107
+1,085
+4% +$7.53K ﹤0.01% 2472
2015
Q3 		$167K Hold
29,022
– – ﹤0.01% 2659
2015
Q2 		$266K Buy
+29,022
New +$324K ﹤0.01% 2557

Other funds holding IOVA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Nationwide Fund Advisors's IOVA Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2017, closing a stake of 29,827 shares — an estimated $231K sold.

Nationwide Fund Advisors first reported a position in IOVA in Q2 2015 and held it in 10 quarters. The position peaked at $1.02M in Q2 2017. 87 funds tracked by Wall St. Rank hold IOVA as of Q4 2017.

  • Nationwide Fund Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2017 after selling out during the quarter.
  • Nationwide Fund Advisors sold 29,827 Iovance Biotherapeutics shares in Q4 2017, an estimated $231K.
  • Nationwide Fund Advisors first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 10 quarters.
  • Nationwide Fund Advisors's Iovance Biotherapeutics position peaked at $1.02M in Q2 2017.
  • 87 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.